StockTipsArenaBeta

Jubilant Pharmova Share price target & analyst calls

Sector:Pharmaceuticals & Biotechnology
₹929.4-6.40 (-0.68%)
As of 21 Oct 2026

Avg 1-year target

All 3 long-term calls are BUY

₹1,433.554.2% above today's price

Jubilant Pharmova's average 1-year share price target is ₹1,433.5, the average of 2 advisors' latest targets. Targets range from ₹1,310 to ₹1,557.

Latest: ICICI Securities ₹1,310 · 8 Feb 2026

3
3 BUY · 0 SELL, all horizons
2
with an active 1Y target
20%
2 of 10 closed calls hit
13
all horizons, open and closed
Watch JUBLPHARMA for new buy/sell callsGet alertsSee 44 Pharmaceuticals & Biotechnology sector analyst picks

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

Jubilant Pharmova target price by brokerage

Each advisor's latest 1-year target · 2 advisors · tap a row for the call

All tips (13)

BUYTarget₹1,310
ISbyICICI Securities+41.0% to target
1 Year* · 4 mo left · 8 Feb 2026 · entry ₹937.65 · via Institutional / Brokerage ResearchP&L -0.9%
BUYTarget₹1,557
VbyVentura+67.5% to target
1 Year* · 3 mo left · 15 Jan 2026 · entry ₹1,066.3 · via Institutional / Brokerage ResearchP&L -12.8%
BUYTarget₹1,415
ISbyICICI Securities+52.2% to target
1 Year* · 14d left · 5 Nov 2025 · entry ₹1,181.2 · via Institutional / Brokerage ResearchP&L -21.3%
BUYTarget₹1,075
RBbyRakesh BansalTarget hit
1–2 Weeks* · 22 Sept 2026 · entry ₹1,050.85 · via CNBC Awaaz.exit ₹1,075
BUYTarget₹1,150
RBbyRakesh BansalStop-loss hit
1–2 Weeks · 29 Sept 2026 · entry ₹1,059.7 · via CNBC Awaaz.exit ₹1,030
BUYTarget₹1,150
RBbyRakesh BansalStop-loss hit
1–2 Weeks · 23 Sept 2026 · entry ₹1,071.9 · via CNBC Awaaz.exit ₹1,040
BUYTarget₹1,150
SJbySandeep Jain, TradeswiftStop-loss hit
1–2 Weeks* · 21 Sept 2026 · entry ₹1,074 · via Zee Business (Live)exit ₹1,010
BUYTarget₹1,120
MKbyMehul Kothari, Anand RathiStop-loss hit
1–2 Weeks* · 15 Jul 2026 · entry ₹1,032.45 · via Zee Business (Live)exit ₹960
BUYTarget₹1,065
ABbyAshish Bahety, Profitmart SecuritiesStop-loss hit
1–2 Weeks* · 15 Jul 2026 · entry ₹1,017.75 · via CNBC Awaaz.exit ₹980
BUYTarget₹1,075
GSbyGaurav Sharma, Globe Capital MarketStop-loss hit
1–2 Weeks* · 14 May 2026 · entry ₹1,012 · via CNBC Awaaz.exit ₹975
BUYTarget₹1,200
VCbyVishvesh Chauhan, ChaseAlphaExpired
1–2 Weeks* · 15 Sept 2026 · entry ₹1,040 · via Zee Business (Live)exit ₹1,067.05
BUYTarget₹1,010
RSbyRajesh SatputeExpired
1–2 Weeks* · 27 Jul 2026 · entry ₹981.9 · via CNBC Awaaz.exit ₹930
BUYTarget₹990
SRbySiddharth Rai MangalaTarget hit
Intraday · 8 Sept 2026 · entry ₹956 · via Zee Business (Live)exit ₹990

* Horizon not stated by the source; assumed from how far the target is from the entry price.

Compare Pharmaceuticals & Biotechnology targets

Most-covered stocks in the sector · average 1-year target

See all Pharmaceuticals & Biotechnology analyst picks